ALB and Huntington disease: In this work, we present a novel approach that combines the properties of integral asymmetric monophasic hybrid cellulose acetate/silica membranes and the power of IBF as a strong HSA binding competitor towards producing HD membranes which target the removal of PBUTs and prevent the infusion of high IBF dosage to patients under HD treatment.